

## Synagis® (palivizumab) Enrollment Form Please complete the form and fax to: 866.823.9966

Please include: 1) Copies of insurance cards (front/back) 2) NICU discharge summary and 3) Most current clinical notes

1. PATIENT INFORMATION (Please print or type clearly)	CLINICAL INFORMATION & MEDICAL
NameToday's Date	ASSESSMENT (CONT'D)
Street Address	State Zip Code Patient has the following condition(s):  Day Cell Phone Cyanotic heart disease (in consultation with a pediatric cardiologist): ICD-10: Acyanotic heart disease (receiving medication to control CHF & will require cardiac surgical procedures): ICD-10
City         State         Zip Code	
Phone Numbers (Include Area Code): Day	
Night Cell Phone	
Date of Birth □ Male □ Female	
Allergies	
Primary CaregiverPhone	Last date received:
Emergency Contact Phone	Patient is younger than 24 months of age and has undergone
INSURANCE INFORMATION (Include copies of insurance card - front and back):  Primary Insurance:Phone	cardiac transplantation during the RSV season. ☐ Yes* ☐ No Date of Transplant:
Name of Cardholder	5. Neuromuscular Disease/Congenital Airway Abnormality with impaired ability to
ID # Group #	clear secretions from upper airway during first year of life: Yes* No
Secondary Insurance:Phone	☐ Severe neuromuscular disease ICD-10:
Name of Cardholder	□ Congenital or other pulmonary abnormality ICD-10:
ID # Group #	6. Profoundly immunocompromised or receiving chemotherapy during RSV season and younger than 24 months of age ☐ Yes ☐ No  ICD-10: Drug regimen:
<b>DELIVERY INSTRUCTIONS:</b> □ Physician's Office □ Patient's Home □ Other:	
2. PRESCRIBER INFORMATION *Indicates Required Field	7. Patient has a diagnosis of Cystic Fibrosis as well as:
·	<ul> <li>□ Clinical evidence of CLD (under 12 months of age)*</li> <li>□ Nutritional compromise (under 12 months of age)*</li> <li>□ Manifestations of severe lung disease (12-24 months of age)*</li> <li>(Previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities</li> </ul>
Prescriber First and Last Name*	
NPI #*DEA #	
Facility NameStreet Address*	on chest radiography or chest computed tomography that persist when stable.)
Street Address*	☐ Weight for length less than 10 <sup>th</sup> percentile (12-24 months of age)*
Phone #* Fax #	4. NICU HISTORY:
Form Submitted By	Did the patient spend time in the NICU? ☐ Yes ☐ No
CONTACT:	If yes, please attach the NICU Discharge Summary
Healthcare Professional Phone #	Was there a NICU/HOSPITAL RSV dose administered?  ☐ Yes – Date(s): ☐ No
3. CLINICAL INFORMATION & MEDICAL	Agency nurse to visit home for injection? ☐ Yes ☐ No
ASSESSMENT	Agency Name:
Patient's Gestational Age: weeks days Birth Weight g/kg/lbs  Current Weight g/kg/lbs Date Recorded:	*PLEASE PROVIDE CLINICAL DOCUMENTATION WHERE REQUESTED
Please document all diagnoses and provide the specific ICD code for each.	RX
<ol> <li>Prematurity: Infants younger than 12 months of age at the start of RSV season and who were born at or before 28 weeks, 6 days gestation.</li> <li>□ ICD-10 (P07.21 through P07.31, please indicate):</li> </ol>	☐ Synagis® (palivizumab): Combination of 50- and/or 100-mg vials Sig: Inject 15 mg/kg IM one time per month
2. Diagnosis of chronic lung disease (CLD) and younger than 12 months of age?	Dispense Quantity: QS Refill xmonths (required)  Other:
☐ Yes*☐ No ICD-10:	☐ Epinephrine 1:1000 amp. Sig: Inject 0.01 mg/kg as directed
☐ Yes* ☐ No Patient required >21% oxygen for at least the first 28 days after birth ☐ Yes* ☐ No Patient is 12-24 months of age, meets all CLD requirements	(dispense only if Synagis® is administered in the home)
above and continues to require medical support for CLD within 6 months of the start of RSV season (check all that apply and provide last date received):	EXPECTED DATE OF FIRST/NEXT INJECTION:Previous injection(s) given? ☐ Yes ☐ No
Oxygen (Date): Corticosteroids (Date): Diuretics (Date):	Please list all previous injection dates:
Prescriber's Signature	Date
	<del></del>

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, and proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.

**866.823.9868 Fax 866.823.9966**